However, regardless of the exact mechanism underlying the additional phagocytosis and trogocytosis upon treatment with CD47 antibody B6H12 specifically in SIRP-β2high AMLs, these data suggest that SIRP-β2high AML patients could significantly benefit from innate immune targeting therapies such as CD47 immune checkpoint inhibitor (ICI). The gene discussed is SIRPA; the disease is acute myeloid leukemia.